GlassScriptPhysician profile
Russell Kevin Daniel
NPI 1376540260
$4,932.47
in general payments reported to CMS, 2019-2025
12 companies · $895 in 2025
The $895 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $441 · 2021: $438 · 2022: $555 · 2023: $759 · 2024: $1,039 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,693.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,065.32 | 2019-2024 | Senza |
| Abbott Laboratories | $937.55 | 2020-2025 | Eterna, Proclaim, Octrode |
| Peerless Surgical INC. | $706.43 | 2019-2021 | |
| Globus Medical, INC. | $695.66 | 2025 | Senza |
| Medtronic, INC. | $198.20 | 2023-2024 | Intellis Adaptivestim |
| Boston Scientific Corporation | $133.58 | 2021-2024 | |
| Fidia Pharma USA INC. | $71.63 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $40.24 | 2023 | Ztlido |
| Arthrex, INC. | $30.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $19.42 | 2023 | Seglentis |
| Arbor Pharmaceuticals, INC. | $17.86 | 2022 | |
| Solventum Corporation | $16.58 | 2025 | Promogran Prisma, Activ.A.C. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.